Press Release: FibroGen Appoints David DeLucia as Chief Financial Officer
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 34% Share Price Rise
FibreGen Shares Are Trading Higher. The Stock May Be Moving on Continued Strength Following a Q3 Earnings Beat Reported on Tuesday.
FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript Summary
FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript
フィブロジェン | 8-K:フィブロジェンは2024年第3四半期の決算を報告します
FibroGen Reiterates Full Year Net Product Revenue Guidance Of $135M-$150M
FibroGen GAAP EPS of -$0.17 Beats by $0.06, Revenue of $46.3M Beats by $11.54M
Earnings Flash (FGEN) FIBROGEN Reports Q3 Loss $-0.17
フィブロジェン | 10-Q:Q3 2024 四半期報告書
FibroGen 3Q Rev $46.3M >FGEN
Earnings Outlook For FibroGen
FibroGen to Report Third Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ:FGEN) Not Doing Enough For Some Investors As Its Shares Slump 27%
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Executive Reshuffles: HON, CIEN, RNG and ASAN Companies in Focus
FibroGen Terminates CFO Juan Graham, Chief Medical Officer Deyaa Adib
FibroGen CFO, CMO to Leave Company by Year's End
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference